1. ScholarBank@NUS
  2. 1. Staff
  3. Staff Publications
Please use this identifier to cite or link to this item: https://scholarbank.nus.edu.sg/handle/10635/237780
DC FieldValue
dc.titlePerspectives on the Risk-Stratified Treatment of Multiple Myeloma
dc.contributor.authorDavies, FE
dc.contributor.authorPawlyn, C
dc.contributor.authorUsmani, SZ
dc.contributor.authorSan-Miguel, JF
dc.contributor.authorEinsele, H
dc.contributor.authorBoyle, EM
dc.contributor.authorCorre, J
dc.contributor.authorAuclair, D
dc.contributor.authorCho, HJ
dc.contributor.authorLonial, S
dc.contributor.authorSonneveld, P
dc.contributor.authorStewart, AK
dc.contributor.authorBergsagel, PL
dc.contributor.authorKaiser, MF
dc.contributor.authorWeisel, K
dc.contributor.authorKeats, JJ
dc.contributor.authorMikhael, JR
dc.contributor.authorMorgan, KE
dc.contributor.authorGhobrial, IM
dc.contributor.authorOrlowski, RZ
dc.contributor.authorLandgren, CO
dc.contributor.authorGay, F
dc.contributor.authorCaers, J
dc.contributor.authorChng, WJ
dc.contributor.authorChari, A
dc.contributor.authorWalker, BA
dc.contributor.authorKumar, SK
dc.contributor.authorCosta, LJ
dc.contributor.authorAnderson, KC
dc.contributor.authorMorgan, GJ
dc.date.accessioned2023-03-02T02:16:50Z
dc.date.available2023-03-02T02:16:50Z
dc.date.issued2022-07-06
dc.identifier.citationDavies, FE, Pawlyn, C, Usmani, SZ, San-Miguel, JF, Einsele, H, Boyle, EM, Corre, J, Auclair, D, Cho, HJ, Lonial, S, Sonneveld, P, Stewart, AK, Bergsagel, PL, Kaiser, MF, Weisel, K, Keats, JJ, Mikhael, JR, Morgan, KE, Ghobrial, IM, Orlowski, RZ, Landgren, CO, Gay, F, Caers, J, Chng, WJ, Chari, A, Walker, BA, Kumar, SK, Costa, LJ, Anderson, KC, Morgan, GJ (2022-07-06). Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood cancer discovery 3 (4) : 273-284. ScholarBank@NUS Repository.
dc.identifier.issn2643-3230,2643-3249
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/237780
dc.description.abstractThe multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.
dc.publisherAmerican Association for Cancer Research (AACR)
dc.sourceElements
dc.subjectHumans
dc.subjectMultiple Myeloma
dc.subjectPrognosis
dc.typeArticle
dc.date.updated2023-03-01T15:12:18Z
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.description.sourcetitleBlood cancer discovery
dc.description.volume3
dc.description.issue4
dc.description.page273-284
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.pdf4.92 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.